VANCOUVER, British Columbia, May 14, 2014 (GLOBE NEWSWIRE) -- Aquinox Pharmaceuticals, Inc. ("Aquinox") (Nasdaq: AQXP ), a clinical stage pharmaceutical company discovering and developing targeted therapeutics for inflammatory disease and cancer, today announced that the company will present a "study in progress" poster on the FLAGSHIP trial of its lead development candidate, AQX-1125, at the 2014 American Thoracic Society (ATS) International Conference. The conference will be held May 16-21, 2014 in San Diego, CA.
AQX-1125, a SHIP1 activator, is currently being investigated in the Phase 2 FLAGSHIP trial, a randomized, double-blind, placebo controlled trial that is enrolling unstable, moderate to severe chronic obstructive pulmonary disease (COPD) patients who have experienced a recent exacerbation and at least two other exacerbations in the prior 18 months. FLAGSHIP's novel trial design utilizes the recently developed EXAcerbations of Chronic pulmonary disease Tool (EXACT), a highly sensitive patient-reported outcome (PRO) measurement tool for evaluating the symptoms of COPD patients. Top line results are anticipated in the first quarter of 2015.
Presentation details:
Publication Number A2889: "The Flagship Study: A 12-Week Phase II Study To Evaluate The Efficacy And Safety Of AQX-1125 Following Exacerbations In Patients With Chronic Obstructive Pulmonary Disease (COPD) By Targeting The SHIP1 Pathway ," S.B. Shrewsbury, et al. The poster will be presented Monday, May 19 from 10:45 A.M. to 12:30 P.M. in Area A (Hall B2-C, Ground Level) Poster Board Number A30.
A pdf of the poster will be available at www.aqxpharma.com following the presentation.
About Aquinox Pharmaceuticals
Aquinox Pharmaceuticals, Inc. is a clinical stage pharmaceutical company discovering and developing novel, small molecule therapeutics targeting SH2-containing inositol-5'-phosphatase 1 ("SHIP1") for the treatment of inflammatory disease and cancer.
Cautionary Note on Forward-looking Statements
Certain of the statements made in this press release are forward looking, such as those, among others, relating to the therapeutic potential of AQX-1125 and the timing of results of the FLAGSHIP trial. Actual results or developments may differ materially from those projected or implied in these forward-looking statements. More information about the risks and uncertainties faced by Aquinox is contained in the company's Quarterly Report on Form 10-Q for the quarter ended March 31, 2014 filed with the Securities and Exchange Commission. Aquinox disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
For more information please visit www.aqxpharma.com .
Brendan Payne, Senior Manager, Investor Relations 604-629-9223 Bianca Nery MacDougall Biomedical Communications 650-339-7533